Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
JCO Oncology Advances · 2025
DOI: 10.1200/oa-24-00033 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2025. Verfasst von Misako Nagasaka und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of California Irvine, Orange, CA. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Regulator of chromosome condensation 1 ( RCC1 ) and RCC2 have been shown to play important roles in the regulation of cell cycle, DNA damage response, and nucleocytoplasmic transport. MATERIALS AND METHODS DNA (592-gene or whole exome) and RNA (whole transcriptome) sequencing was performed at Caris Life Sciences (Phoenix, AZ). Samples were stratified by RCC1 expression quartile thresholds (Q1: low, Q4: high) for small cell lung cancer (SCLC; n = 876), non–small cell lung cancer (NSCLC; n = 21,603), gastric cancer (GC; n = 1,908), pancreatic cancer (PC; n = 5,071), and colorectal cancer (CRC; n = 14,892). Statistical significance was determined using chi-square and Wilcoxon rank-sum tests and adjusted for multiple comparisons (* P < .05). Corresponding analyses were run for RCC2 . RESULTS Median RCC1 mRNA expression was highest in SCLC (14.3 transcript per million [TPM]), followed by GC (9.9), NSCLC (9.9), CRC (9.8), and PC (6.9). Similar to RCC1 , the median RCC2 expressions were highest in SCLC (36.2 TPM). Tumor mutational burden-high rates were positively associated with increasing RCC1 expression quartiles (Q1-4) in NSCLC (31%-41%), GC (7%-22%), and CRC (5%-17%) and with increasing RCC2 expression in NSCLC and CRC only. Higher expression with RCC1 and RCC2 was associated with worse overall survival in NSCLC (hazard ratio [HR] for RCC1 and RCC2 were 1.3 and 1.3, respectively), PC (HR for RCC1 and RCC2 were 1.5 and 1.12, respectively), and CRC (HR for RCC1 and RCC2 were 1.3 and 1.03, respectively). CONCLUSION RCC1 and RCC2 expression is a negative prognostic marker in NSCLC, PC, and CRC. Further studies to investigate RCC1 and RCC2 function at the molecular level may provide opportunities for novel targeted drug development.
Autor:innen und Institutionen
- University of California Irvine, Orange, CA.
- St Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan.
- Karmanos Cancer Institute, Wayne State University, Detroit, MI.
- Georgetown University, Washington, DC.
- Caris Life Sciences, Irving, TX.
- Montefiore Medical Center, New York, NY.
ORCID-Profile: Misako Nagasaka, Brian Warnecke, Sai-Hong Ignatius Ou, Chul Kim, Balazs Halmos, Dave Hoon, Sourat Darabi, Milan Radovich, Emil Lou, George Sledge, Boris C Pasche
Förderung
- NCI NIH HHS
Zitieren
APA
Nagasaka, M., Warnecke, B., Ou, S. I., Bannoura, S. F., Kim, C., Elliott, A., Halmos, B., Hoon, D., Darabi, S., Sukari, A., Radovich, M., Lou, E., Sledge, G., El-Deiry, W., Al-Hallak, M. N., Pasche, B. C., & Azmi, A. S. (2025). Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes. JCO Oncology Advances. https://doi.org/10.1200/oa-24-00033
Vancouver
Nagasaka M, Warnecke B, Ou SI, Bannoura SF, Kim C, Elliott A, et al. Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes. JCO Oncology Advances. 2025. doi:10.1200/oa-24-00033
BibTeX
@article{Nagasaka2025,
author = {Nagasaka, Misako and Warnecke, Brian and Ou, Sai-Hong Ignatius and Bannoura, Sahar F and Kim, Chul and Elliott, Andrew and Halmos, Balazs and Hoon, Dave and Darabi, Sourat and Sukari, Ammar and Radovich, Milan and Lou, Emil and Sledge, George and El-Deiry, Wafik and Al-Hallak, Mohammed Najeeb and Pasche, Boris C and Azmi, Asfar S},
title = {Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes},
journal = {JCO Oncology Advances},
year = {2025},
doi = {10.1200/oa-24-00033}
}
EUVIMED